IP Verse

Combination Of A Pd 1 Antagonist And Eribulin For Treating Cancer - EP3265122

PATENT ANALYSIS

Patent Details

Grant Date
May 4, 2022
Company
EISAI R&D MANAGEMENT CO., LTD.
Oppositions

GENERICS (U.K.) LIMITED

KONIG SZYNKA TILMANN VON RENESSE

PAJARO LIMITED

WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB

More patents of Eisai R&D Management Co., Ltd.

EP3263106

EP3524595

EP3265122

Want to monitor this patent?

Feel free to send us a message here and we will get back to you